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ABSTRACT 
Dengue virus (DENV) is a reemerging infectious agent causing an estimated 50-100 million 
cases annually and is endemic in more than 100 countries. Recently there has been an increase in 
the geographic spread, the overall number, and the severity of disease cases, making DENV an 
increasing threat to public health. The most prevalent of the arboviruses, DENV is introduced 
into human hosts during a vector mosquito’s blood meal; here, virus is deposited into the 
epidermal and dermal layers of the skin. Therefore, elucidating the cutaneous immune response 
to DENV is critical to our understanding of the immune mechanisms involved in protection and 
pathogenesis of DENV and to the development of effective treatments and vaccines. In addition 
to resident T- and B-cells, the skin immune system includes three major populations of innate 
immune cells, dermal dendritic cells (dDCs), dermal macrophages (dMØs), and epidermal 
Langerhans’ cells (LCs). These immune cells are potential targets of DENV infection. The 
receptor profile of dDCs and dMØs indicates that they are susceptible to DENV infection, 
however evidence of this is lacking. LCs are infected following ex vivo inoculation of human 
skin explants, yet their role in DENV pathogenesis remains unclear.  Upon exposure to a 
pathogen, cutaneous immune cells mature and migrate to the cutaneous draining lymph node via 
the draining lymphatics; these functions are critical to the induction of adaptive immune 
responses and to pathogen clearance. It remains unclear how DENV infection affects the 
maturation, migration and survival of cutaneous immune cells. Herein, we use a combination of 
in vitro studies and ex vivo inoculation of healthy human skin explants to explore the role of 
cutaneous immune cells in DENV infection. We investigated the degree to which cutaneous 
immune cells become infected with DENV and measured upregulation of activation markers, 
migration out of the skin, and the life span of infected cells. We discovered that populations of 
cutaneous DCs, as well as dMØs, become infected with DENV upon scarification of skin with 
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virus. In vitro, we confirmed that DENV infection partially inhibits maturation of DCs and 
potentially MØs. Additionally, DENV infection induces DC apoptosis in a caspase-dependent 
manner. These results help to clarify the role of cutaneous immune cells in the 
immunopathogenesis of DENV.    
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1.0  INTRODUCTION 
Dengue (DENV) is the most prevalent arthropod-borne viral disease worldwide causing an 
estimated 50-100 million cases annually, according to the World Health Organization. While a 
majority of these cases are asymptomatic or manifest as a self limiting febrile illness known as 
dengue fever (DF), approximately 500,000 cases progress to a severe forms of the disease, 
known as dengue hemorrhagic fever (DHF). A fraction of  DHF patients develop dengue shock 
syndrome (DSS), which has a case fatality rate of 20% (1). Currently DENV is endemic in more 
than 100 countries located primarily in tropical and sub-tropical regions of the world. However, 
the potential for farther geographic spread is great as it depends solely on the habitable range of 
the vectors, Aedes aegypti and Aedes albopictus (2, 3). The primary vector, A. aegypti, thrives in 
rural and urban settings, while A. albopictus, an increasingly capable secondary vector, is an 
urbanized species that thrives in densely populated regions. Since DENV persists in a mosquito-
human-mosquito transmission cycle, dense populations increase the efficiency of DENV 
transmission and the likelihood of co-circulating serotypes (4). Epidemiological data suggest that 
secondary infection with a heterotypic serotype of DENV is the primary risk factor for 
development of DHF and DSS (5). It is estimated by public health authorities that two billion of 
the world’s population live at risk of acquiring dengue infection. As of July 2009 the two 
mosquito vectors could be found in 28 of the United States, which puts an additional 170 million 
Americans at risk for infection (2, 3). Despite the escalating disease threat there is currently no 
licensed vaccine for DENV, although there is a candidate vaccine in clinical trials, and the ill-
defined disease pathogenesis complicates the development of a vaccine that is both safe and 
effective (6). Due to the vector-borne nature of the virus, elucidating the effects of DENV on the 
primary targets of infection, thought to be the immune sentinels of the skin, will be vital to this 
effort.   
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1.1 DENV BACKGROUND 
1.1.1 DENV: classification, structure, and life cycle 
Dengue virus is a member of the Flavivirdae family, genus Flavivirus, along with many other 
mosquito-borne viruses that are a disease threat to humans such as; West Nile Virus, Japanese 
encephalitis, and yellow fever virus (7). Mature virions have a classic icosahedral shape and are 
approximately 30nm in diameter (8). Upon cell egress the virion acquires a host-cell derived 
lipid by-layer envelope in which 180 copies of the viral membrane (M) and envelope (E) protein 
are embedded (7). This envelope surrounds a viral nucleocapsid formed by multiple copies of the 
viral capsid protein (C); the nucleocapsid houses a single-stranded positive sense RNA genome 
that is approximately 10.7 kilobases in length (9). Interaction of DENV with human myeloid 
cells has been found to involve C-type lectin receptors such as the DC-specific intracellular 
adhesion molecule 3-grabbing non-integrin (DC-SIGN), mannose receptor (MR), and C-type 
lectin domain family 5 member A (CLEC5 or MDL-1) (9-11). However, a wide range of cells 
are permissive to DENV infection, including many mammalian and mosquito cell lines, 
indicating that viral infection can be mediated by multiple receptors or by virion binding to a 
ubiquitously expressed surface molecule.  
Cell entry relies on clathrin mediated endocytosis and results in virions being internalized 
into a Rab5 positive early endosome; maturation and acidification of the endosome leads to 
membrane fusion, uncoating of the nucleocapsid, and release of viral RNA (12, 13). The genome 
is translated into a single polyprotein that is cleaved by cellular and viral proteases, into three 
structural proteins (capsid, C; precursor membrane and membrane, prM/M; envelope, E) and 
seven nonstructural proteins (NS1, 2a, 2b, 3, 4a, 4b and 5) (14). As with other flaviviruses, 
replication occurs in association with the endoplasmic reticulum (ER). There, particle formation 
occurs in ER-organelles (lipid droplets) when the newly synthesized genome is encapsidated 
(15). Association of the prM and E proteins, embedded in the lumen of the ER, is believed to 
cause a structural change that guides virion budding to the golgi (8, 16). pH changes encountered 
during egress through the trans-golgi network result in reorganization of prM and E such that the 
E protein is protected from undergoing conformational changes. This reorganization also creates 
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a cleavage site for the cellular endoprotease furin to cleave prM; removal of pr peptide is the 
final step in the formation of a mature virion (9). 
There are four serotypes of DENV (DENV1-4) which share great sequence homology. 
Within each serotype, nucleotide variation allows for the identification of genotypes. Analysis of 
DENV genotypes has shown that the virus evolves during the course of an epidemic, but it is not 
known how this may contribute to disease severity. However, it has been shown that genetic 
variation of the virus and the host can have an effect on disease severity (17). Regardless, all four 
DENV serotypes are capable of causing asymptomatic infections, as well as a range of disease 
syndromes from DF to DHF and DSS (18). 
1.1.2 DENV pathogenesis and host immune response 
Infection with any of the four DENV serotypes can result in asymptomatic infection, as in the 
majority of cases, or a wide range of clinical symptoms. The least severe form of clinical disease 
is DF, which manifests with the rapid onset of fever, severe headache, myalgia, gastrointestinal 
discomfort, and a rash. In cases that resolve without complication these symptoms subside 
approximately 5-10 days after onset (18). Viral clearance is likely mediated by CD4 and CD8 T-
cells as well as the production of virus neutralizing antibodies (19). The severe form of DENV 
infection (DHF) includes all of the DF symptoms as well as increased vascular permeability, 
liver enlargement, thrombocytopenia, hemoconcentration, and hemorrhagic manifestations (1, 
18). Due to the increased vascular permeability, without appropriate treatment DHF may 
progress to hypovolemic shock syndrome (DSS) and death (17). The most recognized risk factor 
associated with the development of severe forms of DENV illness is previous infection with a 
heterotypic serotype of DENV(5). It is believed that the severity of secondary infection is 
primarily the result of host immune responses, including roles for heterologous antibody 
dependant enhancement of infection, activation of cross-reactive memory T-cells, excessive 
cytokine production, and complement activation. 
Strong epidemiological data suggest that the presence of sub-neutralizing and non-protective 
DENV antibodies, produced during an initial DENV infection, could exacerbate disease upon 
secondary infection. It is believed that this occurs due to a mechanism called “antibody-
dependant enhancement” (ADE), however clinical evidence of this is lacking and the hypothesis 
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remains controversial. It is proposed that pre-existing DENV antibodies, primarily IgG and IgM, 
bind DENV and mediate infection of monocytes (MOs) and macrophages (MØs) via Fc-
receptors (19). This would lead to an increased number of infected cells and amplified virus 
replication; high levels of viremia early in infection is correlated with progression to DHF/DSS 
(20). Infection of MOs results in the production of TNF-α which increases vascular permeability. 
Therefore, enhanced infection and activation of MOs is likely to contribute to the hemorrhagic 
manifestations of DHF/DSS (20).  
The induction of adaptive immune responses is thought to be critical to viral clearance 
during primary DENV infections. However, the presence of non-protective DENV specific 
memory cells during secondary infection may be detrimental (18). Memory T-cells become 
stimulated early in secondary infection and to very high levels. ADE results in increased 
infection of MOs and MØs; this leads to increased presentation of viral antigen and  T-cell 
stimulation (21). Activated T-cells up-regulate production of pro-inflammatory cytokines such as 
IFN-γ and TNF-α which act directly on vascular endothelial cells (1) increasing the likelihood of 
plasma leakage. The presence of low avidity CD8 T-cells may contribute to increased cytokine 
production and fail to aid in viral clearance (1). Reactivation of memory CD8 T-cells results in 
the expansion of cross reactive T-cells that preferentially react to the viral epitopes from the 
primary infection over heterologous viral epitopes from the secondary infection. This 
phenomenon, termed original antigenic sin, results in CD8 T-cells that produce high levels of 
inflammatory cytokine but lose cytolytic activity (17).     
Increased levels of cytokines including IFN-γ, TNF-α, IL-2, IL-6, IL1-β, and IL-8 in patient 
sera is predictive of the development of severe DENV disease (22). Furthermore, the presence of 
cytokines stimulates the production of additional cytokines from neighboring cells resulting in a 
“cytokine storm.” Studies suggest that the damage of endothelial cells during DHF is caused by 
this cytokine storm and not by viral factors (23). Additionally, these cytokines can facilitate viral 
infection. One example of this is the up-regulation of Fc receptor on MOs and MØs in the 
presence of IFN-γ, which leads to amplification of viral replication (17). 
Other mechanisms have been proposed as underlying factors in the severity of DHF. 
Elevated levels of complement activation factors such as C3a, C4a, and C5a in the sera of 
DHF/DSS patients suggests a role for complement, however the mechanisms remain unclear 
(22). Additionally, some DENV antibodies produced during infection are cross-reactive to self-
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antigens. It is possible that cross-reactivity with endothelial cells results in increased apoptosis 
(17), however this remains controversial. Regardless, it is clear that the immune response to 
secondary DENV infections contributes to the manifestations of severe disease symptoms in 
DHF/DSS cases.   
1.2 INNATE IMMUNE CELLS AND DENV 
1.2.1 Origin and function of macrophages and dendritic cells 
Antigen-presenting cells, including MØs and dendritic cells (DCs), belong to a specialized subset 
of leukocytes known as the mononuclear phagocyte system. These cells, along with MOs, are 
critical effectors and regulators of the innate immune response. Extensive research has been done 
to clarify the origins of these cell types and a recent review highlights the advances and short 
falls of that knowledge (24). All three cell types arise from hematopoietic stem cells (HCS); 
developmental pathways diverge in the bone marrow, likely due to varied environmental cues. 
Myeloid precursors (MP) and lymphoid precursors (LP) differentiate from HSCs. It is now 
generally accepted that MO, MØ, and DCs all arise from the MP. Two populations of DCs, 
myeloid (mDC) and plasmacytoid (pDC), are present at low levels in both the blood and 
peripheral tissues. mDCs, which leave the bone marrow as pre-mDCs, are the strongest antigen 
presenting cell of the innate immune system. Upon activation, often through toll-like receptors 
(TLRs), mDCs will assume a mature phenotype, home to the lymph node, and activate 
appropriate adaptive immune responses (25). pDCs, which leave the bone marrow fully 
differentiated, are capable of producing copious amounts of IFN-α in response to single stranded 
RNA, which is critical for innate immune responses against viral infections (25). MØs reside in 
all lymphoid and non-lymphoid tissues; these cells contribute to homeostasis by clearing 
apoptotic cells, necrotic cells and pathogens (24). The origin of MØs is less clear than other 
mononuclear phagocytes, but they are believed to differentiate from blood-borne monocytes 
(24). Other immune cells arise from HSCs and populate lymphoid and non-lymphoid tissues; 
those present in the skin are discussed further in section 1.2.2 and will be an integral part of the 
studies presented in chapter 3.0.  
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1.2.2 Immune cells of the skin  
Due to the vector-borne nature of DENV, these studies will focus mainly on immune cells of the 
skin and monocyte derived DCs (mdDCs) as an in vitro model. In addition to tissue-resident T- 
and B-cells, the skin is populated by a number of innate immune cells, primarily dermal 
macrophages (dMØ), dermal dendritic cells (dDCs) and epidermal Langerhans cells (LCs). The 
origin, phenotype, and function of these cell types are still being elucidated by cutaneous 
immunologists and there is much that remains unclear and controversial.  
1.2.2.1 Dermal macrophages (dMØ) 
dMØ reside throughout the papillary and reticular layer of the dermis. During steady-state 
conditions, dMØs are believed to contribute to tissue homeostasis through the clearance of 
apoptotic cells and the production of growth factors (26, 27). The origin of these cells, along 
with other tissue-resident macrophages, is unclear. dMØs have great phagocytic capacity and 
express a wide array of pathogen-recognition receptors (PRRs). This phenotype allows them to 
recognize and clear pathogens that penetrate the protective barrier of the epidermis (24). 
Following pathogen uptake, dMØs are capable of producing inflammatory cytokines that aid in 
the recruitment of immune cells from the blood (28). Based on their expression of MHC-II 
dMØs likely possess some antigen-presenting capacity in vivo, but in vitro assessments of their 
immunostimulatory capacity (by mixed lymphocyte reactions) indicates that it is quite minimal 
(27). In addition to their dermal distribution and low MHC-II expression, dMØs can be identified 
by their expression of CD163. CD163 is a hemoglobin/haptoglobin complex-binding scavenger 
receptor expressed exclusively on tissue macrophages (27). In situ studies have shown that the 
dMØ phenotype includes MR (CD206) and DC-SIGN (CD209), but lacks the DC markers 
CD1a, CD1b, CD1c, CD11c, and langerin (CD207) (28). It is difficult to distinguish dMØs from 
dDCs based on morphology because dMØs range from compact and stellate to elongated and 
spindled in shape (28). 
1.2.2.2 Dermal dendritic cells (dDC)  
In contrast to dMØs, dDCs have classic DC morphology and phenotype. They are present in the 
papillary (upper) layer of the dermis and: (1) express high levels of MHC-II, (2) efficiently 
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uptake and process antigen, and (3) migrate to the cutaneous draining lymph node to present 
antigen to T- and B-cells (26). dDCs can be identified by expression of the nonpolymorphic 
MHC-like lipid antigen-presenting molecule blood DC antigen-1 (BDCA-1, also known as 
CD1c), with subpopulations identifiable based on the surface markers CD1a (a glycolipid 
presenting class-I like molecule) and CD14 (29). The three subpopulations, are: 
CD1c+CD1ahighCD14-, CD1c+ CD1adimCD14-, and CD1c+CD1a-CD14+ dDCs (27-30). The panel 
of receptors on dDCs remains somewhat controversial; it is generally accepted that MR and 
DEC205 are on all dDC subpopulations. However, whether DC-SIGN is expressed is unclear 
(27-29).  In response to maturation stimuli, dDCs quickly up regulate expression of CCR7, a 
chemokine receptor that binds CCL19 and CCL21 to direct migration of dDCs to the lymph node 
(31). Recent studies have identified a dermal-resident DC that expresses langerin (CD207), 
which was once thought to be found exclusively on epidermal LCs. In contrast to LCs, the 
langerin expressing subset of dDCs are radiosensitive, express the integrin CD103, and 
differentiate from blood monocyte precursors (32, 33). Langerin+ dDCs are part of the CD1ahigh 
subset (30). Functional studies utilizing murine models suggest that this population: (1) migrates 
more rapidly than LCs, (2) colonizes B-cell rich areas of the lymph-node, and (3) are efficient at 
cross-presentation (34, 35). While their immunological role remains unclear it is important to 
recognize them as a distinct dermal population that develop and function independently of 
classic langerin+ epidermal cells.  
1.2.2.3 Langerhans’ cells (LC) 
Another important cell type to consider in skin immunology is the LC. It is believed that MOs, 
which differentiate from the MO, MØ, and DC precursor (MDP) in the bone marrow, populate 
the skin early in life and differentiate into LCs (24). These cells then reside and renew in the 
epidermis during steady-state conditions (36). Experiments using sets of congenic parabiotic 
mice suggest that during minor injury LCs are capable of renewing without the recruitment of 
blood precursors, but that extreme injury and inflammation results in the recruitment of 
CCR2/CCR6 expressing bone marrow derived precursors (36, 37). LCs can be defined 
morphologically by their classic dendritic appearance and the presence of Birbeck granules 
(BG); this racket shaped structure is a subunit of the endosomal recycling compartment and is 
thought to be involved in the uptake of antigen and the internalization of CD207 and CD1a (38). 
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The formation of BGs is dependent on expression of the Ca2+- dependent type II transmembrane 
protein langerin (CD207) (26). While CD207 is a defining marker of LCs it is not limited to this 
cell type (32, 33). In addition to CD207, LCs have the DC markers CD1a and CD1c and lack 
MR and DC-SIGN (37). The role of LCs in induction of immune responses remains a 
controversial issue.  
There is a longstanding belief that LCs are the immune sentinels of the skin with the primary 
function of initiating immune responses to epidermal threats (39). However, recent murine 
models have challenged this belief. In the presence of herpes virus, a highly localized skin tropic 
pathogen, CD8α- LCs do not present antigen in the cutaneous draining lymph node.  They 
transfer antigen from the skin to lymph node-resident CD8α+ DCs for presentation to T-cells 
(40). Contact hypersensitivity (CHS) is a skin inflammatory reaction indicative of a CD8 T-cell 
response following activation by skin immune cells. This measure has been used extensively to 
assess the immune function of LCs using mouse strains in which LCs have been selectively 
removed. These studies have revealed that LCs are not strictly necessary for the induction of 
CHS, which challenges their role as critical antigen-presenting cells. Extreme CHS has been 
observed in LC knock-out mice when compared to wild-type, suggesting an immunoregulatory 
function of LCs (39, 41). Unfortunately, these studies were performed prior to the discovery of 
langerin+ dDCs, which further confounds their results. However, they do suggest that LCs may 
contribute to immune responses in both a stimulatory and suppressive capacity, an outcome 
possibly dictated by cytokines, chemokines, and other environmental immune modulating 
factors.  
1.2.3 Role of skin immune cells in DENV infection 
Current hypotheses of DENV pathogenesis suggest that the virus is injected into the blood 
stream during a mosquito vector’s blood meal. “Spill-over” of the virus enters the epidermis and 
dermis. Here, DENV infection can potentially occur in keratinocytes, LCs, dMØs and dDCs. 
Infected immune cells mature and migrate to the cutaneous draining lymph node. In the lymph 
node additional macrophages and monocytes become infected; this results in viral amplification 
and dissemination via the lymphatics (17). However, data indicating that skin cells become 
infected with DENV are lacking. In vivo data are limited and skewed by the availability of 
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samples; data primarily come from autopsy result of fatal cases of DHF/DSS and may not be 
representative of the typical disease course. According to in situ hybridization, or a combination 
of PCR and virus isolation techniques (42), most cases of severe disease have DENV present in 
the skin. However, the populations of skin cells that are infected have yet to be identified.  
The majority of data regarding infection of skin cells comes from in vitro or ex vivo studies. 
Exposing healthy human skin explants to DENV-2 isolates has resulted in infection of skin cells, 
however it is not clear what cell types become infected and what their consequent phenotype is. 
RT-PCR for the negative-strand DENV-RNA replication intermediate, following ex vivo 
inoculation of healthy skin, suggests that DENV is capable of replication in the skin (43). 
Immunolabeling for the viral non-structural protein-1 (NS1) in cryosections of inoculated skin 
has shown vast amounts of DENV infection in the epidermal stratum basale and very seldom 
infection of cells in the superficial portion of the epidermis, presumably LCs (43). Here, markers 
for activation, maturation, and apoptosis were up-regulated in the presence of virus. However, it 
is unclear whether it is DENV infected or bystander cells that acquire the mature phenotype (44). 
A skin biopsy obtained from the recipient of a live attenuated tetravalent DENV vaccine revealed 
that epidermal cells become sparsely infected with DENV (as detected by the pan-DENV 2H2 
antibody) (45). Co-expression of CD1a on epidermal DENV positive cells suggests that they 
were LCs. Other studies have used cadaveric skin to assess the degree of infection in emigrant 
cells of DENV inoculated skin; these reveal that a large portion (approximately 60%) of MHC-II 
positive skin cells become infected with DENV upon ex vivo inoculation (45). Due to the 
complex phenotypes of cutaneous immune cells, discussed in section 1.2.2, MHC-II and CD1a 
are not sufficient markers to identify the subsets of cells in the dermis and epidermis. In vitro 
infection of purified skin MØs indicates that expression of DC-SIGN renders dMØ susceptible to 
viral entry, but that trafficking DENV to poorly acidified phagosomes limits viral replication 
(46). However, in situ studies of DENV infected dMØ are lacking. In summary, inoculation of 
human skin explants, both cadaveric and healthy, demonstrate that dendritic cells of the skin do 
become infected with DENV (43, 45). Using methods outlined in such studies, as well as other 
skin immunology studies (30), could clarify which immune cells become infected with DENV-2, 
what phenotype they portray, and thus how they contribute to disease pathogenesis. 
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1.2.4 Hypothesis and specific aims 
We aimed to clarify the effects of DENV infection on cutaneous immune cells and hypothesized 
that DENV infects these cells, namely dMØs, dDCs, and potentially LCs, and renders them 
incapable of maturation, migration, and survival. 
 
Aim 1: Determine infectivity of DENV 2 in monocyte derived DCs and the effects of 
infection on function and viability. Hypothesis: mdDCs are susceptible to infection with 
DENV 2; following infection mdDCs will fail to mature and will initiate apoptosis. Approach: 
Immature human monocytes will be cultured in the presence of GM-CSF and IL-4 for five days 
to produce immature mdDCs. Following mock or DENV-2 infection, cells will be assessed by 
flow cytometry for the expression of DENV protein, maturation markers, and apoptotic signals. 
Aim 2: Identify cutaneous targets of DENV infection. 
A) Characterize resident and emigrant immune cell populations in the presence and 
absence of DENV infection. Hypothesis: Immune cells of the skin, both dermal and epidermal, 
can be identified using a panel of antibodies to extracellular proteins. A portion of dDCs, dMØ, 
and potentially LCs will be infected with DENV; some infected cells will migrate out of 
inoculated skin while some will remain in the dermis and epidermis. Approach: Using an 
antibody panel containing: anti-HLA-DR, CD1a, CD1c, CD163, CD207, and anti-DENV1/2, 
flow cytometry analysis of emigrant skin cells will be performed. Emigrant cells will be 
collected 48 hours after inoculation of skin explants with DENV 2 or negative control. Infection 
and staining controls will be performed on BHKs. This antibody panel will also be used to 
perform in situ analysis of resident skin immune cells in cryosections of treated human skin 
explants.      
B) Determine the effects of infection on function and viability. Hypothesis: DENV 
infects dDCs, dMØs, and LCs; infected cells will display an immature phenotype and early 
apoptotic features. Approach: Following inoculation with DENV-2 or negative control, 
migratory cells will be collected and analyzed by flow cytometry. Additionally, skin will be 
sectioned and stained for immunohistochemistry. Infection and staining controls will be 
performed on cytospins of BHKs.          
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2.0  EFFECTS OF DENV ON MONOCYTE-DERIVED DENDRITIC CELLS 
2.1 INTRODUCTION AND BACKGROUND 
Elucidating the effects that DENV infection has on DCs is critical to understanding the role of 
DCs in both innate and adaptive immune responses against DENV infection. Two of the 
identified DENV receptors, MR and DC-SIGN (10, 11), are expressed on immature mdDCs 
rendering them susceptible to DENV infection. The use of mdDCs as a model for circulating 
mDCs may lack biological relevance since circulating mDCs do not express MR and DC-SIGN 
in the absence of inflammatory cytokines (47) and have a mature phenotype when resident in the 
paracortex of the lymph node (48). However, the phenotypic similarities to dDCs make mdDCs 
an appropriate in vitro model for studying the effects of DENV infection of dDCs in vivo. During 
steady state, dDCs have an immature phenotype and express many of the same surface markers 
and receptors as mdDCs, including: CD1a, MR, and possibly DC-SIGN (27, 28, 49). mdDCs 
were used here as a model for dDC susceptibility to DENV and to clarify the effects that DENV 
infection has on DCs in regards to maturation and survival.  
A large body of evidence suggests that immature mdDCs are susceptible to DENV infection; 
however the resultant phenotype has been a topic of conflict. Initial studies reported that 
infection leads to maturation of cells as measured by up-regulation of MHC-II, costimulatory 
molecules CD80 (B7.1) and CD86 (B7.2), the DC maturation marker CD83, and production of 
cytokines (TNF-α and IFN-α) (49, 50). However, populations of mdDCs exposed to DENV 
failed to produce IL-12, a T-cell stimulating factor required for the generation of type 1 T-cell 
responses in cell-mediated immunity (CMI). This finding contradicted the conclusion that DENV 
infected mdDCs were mature and active (49) and prompted further investigation. Subsequent 
studies examined separately the phenotypes of DENV infected and bystander cells. This revealed 
that the mature phenotype observed in DENV exposed cultures was likely the result of bystander 
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(uninfected cells) and not cells directly infected with DENV (44, 51). TNF-α and IFN-α are 
produced by DENV infected cells and are thought to result in the maturation of bystanders. Also 
the presence of these cytokines results in down-regulation of DC-SIGN which likely protects 
bystander DCs from infection. Researchers have had success reversing the immature phenotype 
of DENV infected mdDCs in mixed leukocyte reactions using activated T-cells, but no success 
with soluble stimulating factors (51, 52). Whether DENV induces cell death also remains 
controversial. During acute disease it has been shown that infection results in resistance to 
apoptosis compared to mock infection (50). Conversely, high levels of apoptosis have been 
observed in DENV positive mdDCs when compared to bystander and mock infected cells. 
However, apoptosis of DENV infected cells was only observed at very high MOIs and was 
equated to effects of viral burden (44). 
The immune cells of the skin are thought to be primary targets of DENV infection; however 
there is a lack of biologically relevant evidence for this theory. This is due, in part, to the time, 
funding, and resource constraints that render ex vivo studies difficult to perform. Limited access 
to skin samples, from either healthy or DENV infected individuals, makes it necessary to use in 
vitro derived mdDCs as a model for DENV infection of dDCs.  
2.2 MATERIALS AND METHODS 
DENV isolate: Cells were infected with the prototypical laboratory strain of serotype-2 DENV, 
New Guinea C (NGC). Virus propagation was performed in BHK-21 cell for 6 days, resulting in 
a titer of 5x106 PFUs/ml as measured by plaque assay in BHK-21 cells (propagation and plaque 
assay performed by Randy Stalter). Uninfected BHK supernatants were collected for use as 
negative infection controls. 
DENV specific antibodies: Pan-DENV antibody D3-2H2-9-21 (2H2) was propagated in a 
mouse hybridoma from mice immunized with all four DENV serotypes (ATCC); it binds the 
viral protein prM in the cytoplasmic region of productively infected cells and on the surface of 
mature virions. Anti-DENV antibody 15F3-1 (15F3) was propagated in a mouse hybridoma from 
animals infected with only DENV serotype-1 antigen; it binds the viral NS1 protein from DENV 
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serotype-1 only (ATCC) and was used as a negative control. (Antibody propagation and 
purification performed by Xiangdong Liu).  
Infection of BHK-21 cells: BHK-21 cells were cultured in a T-25 flask in DMEM (2% FBS+ 
Pen/Strep) at 37⁰C (5% CO2) until confluent. At such time the media was aspirated from the 
flask and 100 µl of undiluted virus stock or BHK supernatant (negative control) was added. 
Inoculums were distributed across the cell monolayer by gently hand rocking the flask. 
Following 2 hour incubation at 37⁰, the virus was removed and the cells were washed thoroughly 
with pre-warmed DMEM (2%FBS+ Pen/Strep). Fresh media was added and the cells were 
incubated at 37⁰C (5% (CO2)) for 48 hours. Samples were run on an LSRII flow cytometer and 
analyzed using FlowJo software. 
Staining BHK-21 cells for flow: Media was aspirated and discarded; adherent cells were 
trypsinized and washed in fresh media. Alexa647-fluorophore-conjugated anti-mouse Fab 
fragments were used to label the Fc portion of the pan-DENV antibody 2H2 or the DENV-1 
serotype specific antibody 15F3 (Zenon-Labeling Kit: Invitrogen). These were used for an 
intracellular stain following fixation and permeabilization of cells (BDCytoFix/Perm Kit). 
Additionally, a time course of BHK-21 infection was performed with data collected at 0, 6, 18, 
30, and 48 hours p.i. Samples were run on an LSRII flow cytometer and analyzed using 
FACSDiva software (BD Bioscience). 
Fluorescent microscopy of BHK-21 cells: BHK-21 cells (DMEM+2%FBS+Pen/Strep) were 
incubated (37⁰C (5% CO2)) in 64 well plates containing sterile cover slips until cells were 
confluent and adherent on slips (40 hours). Media was replaced with 200 µl of fresh media or 
1:10 dilutions of day 6 BHK supernatant or DENV. Following a 2hr incubation (37⁰C (5% CO2)) 
inoculants were aspirated and cover slips were washed and cultured in fresh medium for 24 
hours. Cells were fixed and permeabilized (BD CytoFix/Perm) and stained with the 
unconjugated primary antibodies IgG2a (BD Pharmingen) and 2H2 (ATCC) followed by a goat-
anti-mouse Alexa488 secondary antibody (Invitrogen). Hoechst stain, a membrane permeable 
stain which binds DNA at A-T regions allowing for visualization of nuclei, was applied. Cover 
slips were inverted and adhered onto microscope slides with gelvatol. Slides were viewed on an 
Olympus Provis microscope with a fluorescent light source (University of Pittsburgh, Centers for 
Biological Imaging).  
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Deriving DCs from CD14+ monocytes: DCs were propagated from purified monocytes as 
previously described (53). Briefly, human monocytes, previously isolated via CD14+ microbead 
selection from healthy human blood donors, were cultured in DC media supplemented with GM-
CSF and IL-4. Cells were cultured in 6 well plates at a density of 3×105 cells per ml and 3 ml per 
well (37⁰C (5% CO2)). On day two and four of the incubation fresh cytokine supplemented 
media was added to each well. Immature mdDCs were infected on day five. 
DENV infection of mdDCs: Undiluted NGC virus (titer 5×106 PFU/ml) or day 6 BHK-21 
supernatant was added to each well (3ml) to obtain a virus dilution of 1:10 and an infectious dose 
of approximately 1 PFU/cell. Inoculants were distributed by gently swirling culture plate. At no 
point during the incubation (37⁰C (5% CO2)) were inoculants removed; cells were harvested 48 
hours post infection using gentle agitation with FACS buffer to remove adherent DCs. DENV 
susceptibility was assesses by flow cytometry using intracellular staining with Alexa647-Zenon-
conjugated 2H2 or 15F3.  
Maturation assay: The phenotype of mdDCs following 48 hours of DENV or mock infection 
was assessed by flow cytometry using extracellular antibodies: HLA-DR (PerCp-Cy-5),CD80 
(FITC), CD86 (PerPc), CD83 (PE) or appropriate isotypes. Cells were fixed and permeabilized 
prior to incubation with Alexa647-Zenon-conjugated anti-DENV 2H2 or 15F3. Subsequent 
experiments assessed the capacity of DENV infected mdDCs to mature in response to external 
stimuli. A cytokine cocktail containing: polyI:C (20µg/ml), rhIFN-γ (1,000u/ml), rhesusTNF-α 
(50ng/ml), and rhesus IL-1β (25ng/ml) was added to wells 2 hours p.i. Following 48 hours of 
stimulation/infection cells were stained with surface-labeling antibodies as above and fixed and 
permeabilized prior to staining with Alexa647-Zenon-labeled DENV antibodies. Analyses were 
performed using an LSRII flow cytometer and FACSDiva software (BD Bioscience). Antibody 
information is available in Table 2. 
Apoptosis assay: To detect apoptosis in mock and DENV infected mdDCs, cells were stained 
for flow cytometry with a U/V dye (that is excluded by intact cell membranes) to differentiate 
live cells from dead and CD14 (PE) or isotype control. Following fixation and permeabilization 
(BDCytoFix/Perm) the cells were stained with anti-active-caspase-3 (FITC) or isotype, and anti-
Dengue 2H2 (Alexa647-Zenon-conjugated). Samples were run on an LSRII flow cytometer and 
analyzed using FACSDiva software (BD Bioscience). Antibody information is available in Table 
2. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Productive DENV infection of BHK-21 cells 
After 48 hours of infection approximately 45% of the infected BHKs are positive for prM, 
detected with the pan-DENV antibody 2H2, while no staining is detected with the serotype-1 
specific antibody (15F3) or in mock infected cells (Figure 1A). Additional staining using a 
primary/secondary antibody protocol was performed to confirm that the Zenon-labeled antibody 
stained with similar efficiency (data not shown). 
 
  
 
Figure 1: BHK-21 cells are susceptible to DENV infection:  
A) Mock infected BHK-21 cells (left) and DENV-2 infected BHK-21 cells (right). Histogram of fluorescent 
intensity of unstained cells (gray line), Alexa647-Zenon-conjugated DENV-1 antibody 15F3 (blue line), or 
Alexa647-conjugated pan-DENV antibody 2H2 (green line) (Data representative of >3 replicates). B) The 
percentage of DENV positive BHK-21 cells following infection as detected by Alexa647-Zenon-conjugated pan-
DENV 2H2 antibody.   
 
 
A time course of BHK-21 infection was performed to confirm the observation made at 48 
hours p.i., since the 2H2 antibody is not necessarily indicative of a productive viral infection 
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(Figure 1B). The minimal amount of prM detected at the six hour time point is likely the staining 
of extracellular virus particles; the continuous growth following this early time point is 
characteristic of a productive infection. Additionally, a sample of DENV infected BHKs was 
taken at the 48 hour time point and stained without permeabilization; there was a similar level of 
prM detection with this method as at the 6 hour time point (approximately 3-5%) (data not 
shown). Taken together, these data suggest that our isolate of NGC is infectious and that the 2H2 
and 15F3 antibodies are specific and sensitive for virus detection. Subsequent infections of 
mdDCs and skin explants were accompanied by a BHK infection as a control for viral 
infectivity. 
2.3.2 Fluorescent microscopy of DENV infected BHK-21 cells   
Fluorescent microscopy was performed to confirm the results seen by flow cytometry. Based on 
the infectious life cycle of DENV discussed in section 1.1.1, we expect to see staining for viral 
prM protein in the cytoplasmic region of productively infected cells, as depicted in Figure 2. 
These images confirm the infection detected by flow cytometry in Figure 1.  
 
 
 
Figure 2: DENV infection of BHK-21 cells visualized using fluorescent microscopy 
BHK-21cells stained with the unconjugated pan-DENV 2H2 (1⁰) and goat-anti-mouse Alexa488 (2⁰) antibody 
(green). Hoechst nuclear stain (blue). Left: mock infected cells. Right: NGC infected cells. Images are representative 
of two replicates. 
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2.3.3 Immature mdDCs are susceptible to DENV infection 
Immature human mdDCs were used as an in vitro model for DENV infection of dDCs. The 
expression of MR and CD1a on these cells makes them an appropriate surrogate to investigate 
the susceptibility of dDCs to DENV. The mdDCs were infected on day 5 of culture; at this time 
>90% of the cells had differentiated into CD14- cells but remained immature based on 
expression of MHC-II, CD80, CD86, and CD83 (data not shown). Based on trypan blue 
exclusion, the survival of cells in the presence or absence of virus was similar at 48 hours p.i., 
with viable cell counts equal to 1.5×106 and 1.3×106 respectively. Figure 3A shows typical 
results seen in DENV infected populations of immature mdDC. Approximately 65% of cells up 
regulate expression of MHC-II and 15-30% of cells are DENV positive. In order to confirm that 
the level of prM positive cells seen at 48 hours is indicative of a productive DENV infection, a 
time course was performed (Figure 3B). 
 
 
 
Figure 3: mdDCs become productively infected with DENV 
A) DENV infected mdDCs assessed for forward and side scatter (left) HLA-DR (PerCP) (middle) and Alexa647-
conjugated pan-DENV antibody 2H2 (right). Data are representative of >3 independent replicates. B) The 
percentage of DENV positive mdDCs following infection as detected by Alexa647-Zenon-conjugated pan-DENV 
2H2 antibody. 
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2.3.4 DENV infection inhibits maturation of mdDCs 
In the presence of appropriate stimulation, DCs become mature and activate and home to the 
lymph node to activate T- and B-cells in the germinal center. This mature/active phenotype can 
be assessed by the expression of certain cell surface markers that are required for DC-mediated 
T- and B-cell activation and proliferation. Amongst these are the immune synapse co-stimulatory 
molecules CD80 and CD86 (or B7.1 and B7.2 respectively) (25, 54), MHC-II for efficient 
antigen presentation, and CD83 to reduce the threshold of T- and B-cell activation (55). At 48 
hours p.i. mock infected populations of mdDCs were generally 50-60%MHC+, 20-30%CD80+, 
20-40%CD86+, and 0-5%CD83+.The presence of DENV results in 15-30% infection but no up-
regulation of maturation markers, generally: 50-60%MHC+, 20-40%CD80+, 20-40%CD86+, and 
0-5%CD83+. Interestingly none of the DENV positive cells become CD83 positive and only a 
portion (approximately 30-50%) of the DENV positive cells express CD80 and CD86 (Figure 4). 
The previously documented “bystander effect”, where DENV infected cells fail to mature but 
bystander cells acquire a mature phenotype (44, 49), was not evident in these data. If the lack of 
maturation in DENV infected DCs is mirrored in vivo it would result in a diminished capacity of 
infected DCs to clear virus and initiate appropriate adaptive immune responses.  
To assess whether soluble external stimuli can restore DENV infected mdDC maturation, 
cells were exposed to a cytokine cocktail two hours p.i. The cocktail used contained: (1) the 
synthetic dsRNA analog poly I:C which induces DC maturation via TLR3 signaling, and (2) 
three pro-inflammatory cytokines, rhIFN-γ, rhesusTNF-α, and rhesusIL-1β. It was confirmed 
that the rhesus cytokines were >95% identical to human by both amino acid and protein 
sequence (data not shown). Representative data of MHC-II, CD86, and CD83 expression are 
displayed in Figure 4. Cytokine stimulation results in maturation of bystander cells and the 
partial restoration of infected mdDC maturation. MHC-II and CD86 are up-regulated on DENV+ 
cells in the presence of the cytokine cocktail, while CD83 remains absent from all DENV+ cells. 
The reduction in overall DENV infection makes it difficult to fully assess maturation. Both poly 
I:C and IFN-γ have potent anti-viral effects and likely resulted in the inhibition of secondary 
(and higher) rounds of infection (49). Often the use of other maturation stimuli are employed 
when working with mdDC, such as TLR 7/8 agonists, LPS, and CD40L (49, 52), however, these 
stimulants failed to up-regulate CD83 in control experiments and thus were not considered 
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effective (data not shown). Taken together these data suggest that DENV infection does not 
result in the maturation and activation of DCs; however, in the presence of pro-inflammatory 
cytokines the immature phenotype can be partially reversed. 
 
 
 
Figure 4: DENV partially inhibits mdDC maturation 
Expression of MHC-II, CD86, and CD83 (X-axes) vs. Alexa647-conjugated pan-DENV antibody 2H2 (Y-axis) in 
mock infected (top row) and DENV infected (second row) mdDCs in the absence of cytokine cocktail maturation 
stimuli and after stimulation with cytokine cocktail (bottom rows). Representative data of two experimental 
replicates. 
2.3.5 DENV infection induces apoptosis in mdDCs 
During viral infection it is critical to mount an appropriate adaptive immune response. DCs play 
a critical role here, in which they become active, mature, and migrate to the lymph node to 
activate T- and B-cell mediated responses. Therefore, survival of infected DCs is vital in DENV 
clearance. To establish whether mdDCs survive during DENV infection, the level of active-
caspase-3 was measured in DENV and mock infected cells. Caspase-3 is an intracellular cysteine 
protease activated during early apoptosis downstream of both the intrinsic and extrinsic cell 
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death pathways (via caspase-8 or -9). Caspase-3 becomes cleaved and can be recognized in this 
active form using an anti-active-caspase-3 antibody (BD). The gating scheme is pictured in 
Figure 5; dead cells and cells expressing CD14 were excluded, the overall percentage of active-
caspase-3 positive cells was analyzed, and finally the percentage of active-caspase-3 positive 
cells in a defined number of DENV infected and bystander cells was assessed.  
 
 
 
Figure 5: Enhanced apoptosis of DENV infected mdDCs compared to bystander cells 
Viable mock and DENV infected mdDCs selected by forward and side scatter and exclusion of live/dead dye. CD14 
(PE) negative cells assessed for expression of active-caspase-3 (FITC) and Alexa647-conjugated pan-DENV 
antibody 2H2. Equal numbers of DENV+ and bystander cells are 15.3% and 1.6% active-caspase-3 positive, 
respectively. 
 
 
Following 48 hours of treatment with virus or negative control the overall survival based on 
trypan blue exclusion does not differ between populations (discussed in 2.3.3); however this 
method of survival analysis is dependent on the late stage characteristic of membrane 
fractionation. Analyzing earlier stages of cell death (activation of caspase-3) reveals that 9-15% 
of DENV infected cells are apoptotic, while less than 2% of bystander and mock infected cells 
are undergoing apoptosis. DENV infected cells are significantly more apoptotic than uninfected 
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or bystander cells (p=0.0061 and 0.0076 respectively) (Figure 6). Taken together these results 
indicate that DENV infection has deleterious pro-apoptotic effects on DCs.  
 
 
 
Figure 6: DENV infected mdDCs significantly more apoptotic than bystander and mock infected cells 
Percent active-caspase-3 positive mock infected mdDCs (left), bystander mdDCs (middle) and DENV(+) mdDCs 
(right). Unpaired T-test of the differences of means between: mock infected and bystander cells p=0.5385, mock 
infected and DENV(+) cells p=0.0061, bystander and DENV(+) cells p=0.0076. 
 
 
These studies clarify the effects of DENV infection on mdDCs in terms of maturation and 
survival. Our results indicate that populations of mdDCs exposed to DENV fail to mature 
beyond the level that is observed in mock infected cells. We found that the immature phenotype 
of DENV infected mdDCs can be partially reversed in the presence of soluble factors, namely 
three pro-inflammatory cytokines, IFN-γ, TNF-α, IL-1β, and a synthetic TLR3 ligand (poly I:C). 
However, the presence of these stimuli fails to restore the expression of CD83 on DENV infected 
DCs. This could be indicative of a specific down-modulation of CD83 induced by a yet 
unidentified viral factor. These data are contradictory to work that suggesting that the immature 
phenotype of DENV+ DCs is only reversed in the presence of activated T-cells (51, 52). 
Additionally, our work shows that DENV infected DCs become apoptotic at an MOI of 
 22 
1PFU/cell. This contradicts findings that DC apoptosis occurs as a result of viral burden and is 
only induced at MOIs greater than five (44). 
The current hypothesis regarding the introduction and dissemination of DENV involves 
immune cells of the skin. Mosquitoes deposit virus into the epidermis and dermis in the course of 
a blood-meal. Here, DENV infects cutaneous antigen-presenting immune cells. These cells are 
thought to mature and migrate to the cutaneous draining lymph node resulting in infection of 
MØs and MOs. The amplification and dissemination of virus then continues via the lymphatics 
(17). However, the results presented here indicate that DENV infected DCs may not contribute to 
the dissemination of virus or the induction of adaptive immunity due to their failure to acquire a 
mature/active phenotype. DENV may evade the immune response by inhibiting DC migration to 
the lymph node and by inducing DC apoptosis. Further studies are needed to understand the 
mechanisms of how DENV induces these deleterious changes in DCs. 
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3.0  EFFECTS OF DENV ON CUTANEOUS IMMUNE CELLS 
3.1 INTRODUCTION AND BACKGROUND 
The skin is densely populated with mononuclear phagocytes that are responsible for monitoring 
the environment for pathogens and initiating appropriate immune responses. Immune cells of the 
skin include dermal macrophages (dMØ), dermal dendritic cells (dDCs) and epidermal 
Langerhans cells (LCs). Because of the vector borne nature of DENV it is important to 
understand the role that these cells play in infection. Currently it is believed that they are targets 
of infection and that they contribute to the spread of virus via the lymphatics (17). However, 
there is a limited body of evidence supporting this hypothesis. Previous studies involving 
inoculation of healthy and cadaveric human skin explants, as well a biopsy of one symptomatic 
recipient of a tetravalent DENV vaccine, suggest that cutaneous cells with dendritic morphology 
become infected with DENV (43, 45). However, a comprehensive phenotype of infected skin 
cells has not been established and it is therefore unclear whether dMØ, dDCs, and/or LCs are 
DENV targets. Developments in the field of cutaneous immunology have resulted in a panel of 
antibodies that can be used to characterize resident and emigrant cell subsets using flow 
cytometry and in situ analyses. The phenotypes of skin immune cells are discussed in section 
1.2.2 and summarized in Table 1. Methods outlined in previous DENV studies, as well as skin 
immunology studies, can be used to clarify the degree to which cutaneous immune cells become 
infected with DENV-2, what phenotype they portray, and how they contribute to disease 
pathogenesis.  
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Table 1: Skin immune cell phenotypes 
Cell Marker CD1a CD1c LANGERIN/CD207 MR/CD206 DCSIGN/CD209 CD163 
Cell Type       
Langerhans’ 
Cells: YES YES/NO YES NO NO NO 
Dermal DCs:       
Subset 1 HIGH YES YES/NO YES NO NO 
Subset 2 DIM YES NO YES NO NO 
Subset 3 NO YES NO YES NO NO 
Dermal MØ: NO NO NO YES YES YES 
3.2 MATERIALS AND METHODS 
Skin explants: Methods were adapted from skin studies in the simian model (unpublished data). 
Briefly, healthy human skin explants from subjects undergoing elective surgery were received 
and cultured within four hours of removal. Samples were processed in two ways: (1) subdural fat 
and connective tissue were trimmed from the dermal side and skin was cultured full-thickness or 
(2) a hand-held dermatome was used to render split-thickness skin with a final thickness of 
≈0.37µm. Skin was cut into 1-2 inch squares, rinsed with 1xPBS followed by DC media, and 
placed dermal side down onto 50 mesh grids in 60x15mm culture dishes.  
Inoculation and culture conditions of skin explants: Split-thickness skin was inoculated via 
scarification (30). Varied concentrations of DENV or negative control were placed on the 
epidermis of sections; a 27 gauge needle was used to create superficial scratches through the 
inoculums. Full-thickness skin was inoculated by injection. DENV or negative control were 
injected with a 29 gauge needle; injections were as superficial as possible and resulted in a 
visible bubble of inoculant (≈100µl) trapped under the epidermis. Scarification/injection was  
performed without media in culture dishes to ensure that infection of emigrant cells was not due 
to virus spilling into the media. Following a two hour incubation (37⁰C (CO2 5%)) pre-warmed 
DC media was added underneath grids; incubation continued at 37⁰C for 48 hours.  
Quantification of migratory cells: Migratory cells were harvested by agitation with FACS 
buffer, passed through a 70µm cell strainer and washed 1x with 10ml of FACS buffer. Red blood 
cells were lysed with 1xACK. The number of live migratory cells was assessed by trypan blue 
exclusion. Skin was removed from mesh grids, rinsed with 1xPBS, and scanned or traced to 
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obtain exact size measurements. Open source NIH software (ImageJ) was used to quantify the 
number of migratory cells per unit area of skin.   
Staining migratory cells for flow cytometry: Extracellular antibody stains included: HLA-DR 
(APC-Cy7), CD1a (PE-Cy5), CD1c (Pacific Blue), CD163 (FITC), and langerin (CD207) (PE). 
Cells were fixed and permeabilized (BD CytoFix/Perm) prior to intracellular staining with 1µg 
of Zenon-conjugated Alexa-647 2H2 or 15F3. Samples were run on an LSRII flow cytometer 
and analyzed using FlowJo or FACSDiva software. Additional antibody information is available 
in Table 3. 
Processing skin samples for in situ analyses: Mock and DENV infected skin samples were 
sucrose infused (30% sucrose, overnight, 4⁰C) and snap-frozen with or without 2%PFA fixation. 
Samples for immunolabeling were embedded in optimum cutting temperature (OCT) compound 
and sectioned to 6µm thickness on a MicroCryotome (University of Pittsburgh, Centers for 
Biological Imaging).  
In situ staining for cutaneous immune cells and DENV: Skin cryosections were maintained at        
-20⁰C until immunolabeling was performed (within two weeks of sectioning). Sections obtained 
without fixation were post-fixed in ice cold acetone for 5 minutes. Prior to applying primary 
antibodies slides were thawed (10 minutes at room temp), rehydrated with 1xPBS, and blocked 
with 2%BSA or 20% goat serum. Unconjugated primary antibodies including: mouse anti-HLA-
DR (1:100), mouse anti-CD1a (1:100), mouse anti-CD1c (1:200), mouse anti-CD163 (1:200), 
mouse anti-DC-SIGN/CD209 (1:250), and mouse anti-MMR/CD206 (1:200) were diluted in 
either 0.5%BSA or 2% goat serum corresponding to the blocking method. Primary antibodies 
were applied for 1 hour. Isotype specific secondary antibodies (Invitrogen) goat-anti-mouse 
Alexa 549 (IgG1) or Alexa 647 (IgG2a and IgG2b) or Alexa 546 Fab fragments were applied for 
30 minutes. Staining for DENV was performed with unconjugated or biotinylated 2H2 overnight 
at 4⁰C prior to cell-surface marker staining. Secondary antibodies used for virus detection were 
Alexa 488 or streptavidin Alexa 488 or 647. Hoechst stain was applied for nuclear visualization. 
Cover slips were adhered with gelvatol. Slides were viewed on an Olympus Fluoview confocal 
microscope (University of Pittsburgh, Centers for Biological Imaging). Antibody information is 
available in Table 4.    
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3.3 RESULTS AND DISCUSSION 
3.3.1 Emigrant cutaneous immune cells from split- and full-thickness skin 
Emigrant cells from split-thickness skin were collected and stained as described in section 3.2; 
the antibody panel is detailed in Table 3. Viable cells were gated by side and forward scatter and 
approximately 30-40% of the migratory population was viable based on this criterion (Figure 7). 
Expression of MHC-II was used as the first inclusion criteria for defining migratory DCs and 
MØs. Averages of 65-80% of viable cells were positive for MHC-II across three replicates; this 
number equates to 12-25% of the total migratory cells being classified as immune cells. CD1a 
and CD1c were used to define dDC populations; three populations were apparent based on 
CD1a: CD1a-, CD1adim/medium, and CD1ahigh. CD1a- and CD1adim/medium populations stained 
brightly for CD1c. Cells of the CD1ahigh population, and to a lesser extent the CD1adim/medium 
subgroup, expressed CD207 (langerin); about 10% of all MHC-II positive emigrant cells express 
CD207. The origin of these CD207+ cells is not clear since epidermal LC and a subset of dDCs 
have been shown to express CD207 (32, 33). Further staining with CD103 would be necessary to 
differentiate CD207+ dDCs from LCs. Alternatively, the separation of the dermis and epidermis 
would clarify the origin of these langerin positive cells. However, the process of separating 
dermis from epidermis, often via collagenase digestion, is likely to alter the phenotypes of 
migratory cells and thus this method was avoided.  
Other emigrant populations remain undefined based on flow cytometry and require further 
investigation. Approximately 20% of cells that express CD1a do not express CD1c or CD207; 
this is unexpected based on the currently accepted phenotypes of cutaneous immune cells (29) 
(Table 1). Additionally, there is a rather large portion of MHC-II positive cells that fail to stain 
for any other antibodies in the panel (Figure 7). These cells express lower levels of MHC-II than 
cells that stain for DC markers; this phenotype is characteristic of dMØs (see 1.2.2). However, 
without the inclusion of CD163 (the defining cell-surface marker for dMØs) it is not possible to 
identify these cells as such. This MHC low population could also include keratinocytes, which 
up-regulate this marker in the presence of pro-inflammatory stimuli (56). It is unlikely that 
DENV infection is the only source of pro-inflammatory stimuli since the proportion of these 
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cells is equivalent in DENV and mock infected samples (data not shown). It is possible that the 
trauma from surgery and ex vivo processing up-regulates MHC-II expression on keratinocytes. 
 
 
 
Figure 7: Emigrant cells from split-thickness skin 
Emigrant cells from DENV inoculated skin after 48hrs culture: viable cells selected by forward and side scatter and 
HLA-DR(APC-Cy7) expression. HLA-DR+ cells contained three populations based on CD1a(PE-Cy5): CD1a- cells 
and 80% of CD1adim/medium cells express CD1c+ (PacificBlue) (left and middle arrows), CD1ahigh cells are CD207+ 
(PE) (right arrow). Data are representative of three independent experiments performed on skin samples from three 
individuals.  
 
 
One disadvantage of using a dermatome to create split-thickness skin sections is that it 
stimulates the migration of dDCs, dMØs, and potentially LCs. Therefore, we also investigated 
DENV infection using full-thickness skin (Figure 8). Here, we cultured full-thickness skin in the 
presence and absence of virus. Emigrant cell collection and staining procedures are outlined in 
section 3.2 and details of antibodies are summarized in Table 3. Viable cells were gated based on 
side and forward scatter; an average of 20% of the total migratory population was viable based 
on this criteria. Only cells with proportionate area and height, indicative of single events, were 
analyzed further (Figure 8). As before, expression of MHC-II was an inclusion criterion for 
defining migratory immune cells. CD1a- and CD1adim/medium phenotypes were evident amongst 
CD1c+ cells; the CD1ahigh population was diminished when compared to migratory cells from 
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split-thickness skin (see Figure 7). The small fraction of CD1ahigh cells co-expresses 
CD207/langerin. However, the total percentage of CD207 expressing cells was <3%. It is likely 
that cells from the epidermis failed to migrate out of full thickness skin; this would explain the 
reduction in MHC-II+ cells as well as the lack of CD207+ cells. Inclusion of CD163 revealed that 
about 10% of MHC-II+ cells are dMØs, which express CD163 and fail to stain for the CD1 
markers and CD207. 
 
 
 
Figure 8: Migratory cells from full-thickness skin  
Emigrant cells from DENV inoculated skin after 48hrs culture: viable cells selected by forward and side scatter (not 
shown), forward scatter height and area (single events) and HLA-DR(APC-Cy7) expression. MHC-II+ contained 
two populations based on CD1a(PE-Cy5): CD1a- cells and 75% of CD1adim/medium cells express CD1c+ (PacificBlue) 
(left arrow), 10% of CD1a- cells are CD163+ (middle arrow). Minor population of CD1ahigh cells are CD207+ (PE) 
(right arrow). Results are representative of four experimental replicates performed on skin explants obtained from 
four individuals. 
 
 
Again, there are migratory populations that cannot be defined based on the current staining 
protocol. 20-30% of cells that express CD1a do not express CD1c or CD207, which does not fit 
the defined phenotype of any cutaneous immune cells (29) (Table 1). One possibility, in the case 
of full- and split-thickness emigrant cells, is that cells expressing only MHC-II and CD1a 
represent dDCs and LCs that have down-regulated CD207 upon migration. It has been shown 
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that langerin expression is lower upon arrival at the cutaneous draining lymph node (35). 
Additionally, studies have shown that langerin is internalized upon migration (57) and therefore 
may have been missed in the extracellular staining performed here (30). A small population of 
MHC-II positive cells does not stain for DC or MØ markers. As discussed before (page 26) it is 
likely that these represent keratinocytes that have up-regulated MHC-II in response to pro-
inflammatory stimuli.  
Emigrant cells from split- and full-thickness skin explants were stained for the presence of 
DENV using the Alexa647-Zenon-conjugated anti-DENV 2H2; DENV positive cells were not 
detected in the MHC-II+ cells that migrate out of skin at 48 hours p.i. (data not shown). In vitro 
data suggest that infected DCs fail to mature and thus may fail to migrate out of the skin. 
Alternatively, DENV infected cells could migrate from the skin but rapidly undergo apoptosis 
and not be detected in the emigrant population. Finally, infection rates could be at the low end of 
the range of detection by flow cytometry; this would inhibit additional studies aimed at 
identifying the phenotypes of infected cutaneous cells using the methods established here. 
3.3.1.1 Quantification of skin emigrant cells  
Live emigrant cells from full-thickness skin were counted, based on trypan blue exclusion, and 
are summarized in Figure 9. A paired t-test comparing the difference of the means reveals that 
the number of emigrant cells from mock and DENV infected skin is not significantly different 
(p=0.1492). 
  
 
 
Figure 9: Quantification of migratory cells from full thickness skin 
Live emigrant cells per square inch of full-thickness mock and DENV inoculated skin. Paired T-test comparing the 
difference of the means p=0.1492 (left) (n=5). Proportions of cutaneous immune cell subsets as a percentage of the 
total MHC-II positive emigrant cells (right) (representative of four individual replicates).  
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Typically, 50% of viable cells from full-thickness skin were positive for MHC-II; this 
equates to 7-13% of emigrant cells being classified as cutaneous immune cells. This percentage 
remained the same between DENV infected and uninfected skin, as did the proportions of 
subpopulations of immune cells (Figure 9). On average; 70% of emigrant cells were DCs defined 
by expression of CD1c, approximately 3% of cells express CD207/langerin, and 10-15% of 
MHC-II+ cells were dMØs. 
3.3.2 In situ cell characteristics 
Cryosections of full- or split-thickness skin were cut in cross-section and stained as described in 
section 3.2. Briefly, 6µm sections were cut from either PFA fixed or unfixed skin samples; 
sections from unfixed skin samples were post-fixed in acetone. Following blocking, primary 
antibodies to cell-surface markers were applied. These markers included: mouse anti-HLA-DR, 
CD1a, CD1c, CD163, DC-SIGN/CD209, and MR/CD206. Polyclonal secondary antibodies used 
included goat-anti-mouse polyclonal Alexa488 or isotype specific Alexa-647 or -549. Initially, 
cell-surface staining was performed to assess the specificity of antibodies and the distribution of 
their epitopes. These experiments confirmed that MHC-II is expressed in both the dermis and 
epidermis while expression of CD163, CD209, and CD206 is restricted to the dermis (Figure 
10). While not evident in Figure 10, additional staining revealed that langerin (CD207), CD1a, 
and CD1c were expressed throughout the skin (evident in Figure 11 and Figure 13). This is 
expected based on the phenotypes of LCs and dDCs discussed in section 1.2.2.  
In order to clarify the role of cutaneous immune cells in DENV pathogenesis, it is important 
to identify the subpopulations that become infected. It is currently accepted that three 
populations of dDCs are present in the skin during steady-state; these populations are 
CD1c+CD1ahighCD14-, CD1c+ CD1adimCD14-, and CD1c+CD1a-CD14+ (27-30). Expression of 
langerin has been documented on dDCs that express high levels of CD1a (Figure 7) (30, 32, 33). 
dMØs fail to express the DC markers CD1a and CD1c, but are defined by expression of CD163 
and dermal residence (27). Both dDCs and dMØs express MR, however the expression of DC-
SIGN on these two cell types remains unclear (27, 28). In order to clarify the phenotypes of 
cutaneous immune cells dual staining was performed.  
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Figure 10: In situ staining for the distribution of immune cell markers and receptors 
Mock inoculated skin sections (6µm) stained for (left to right): m α HLA-DR+g α m IgG2a specific Alexa647 
(orange), m α CD1c+polyclonal g α m Alexa488 (green), m α CD209+g α m IgG2b specific Alexa647 (yellow), m α 
CD206+polyclonal g α m Alexa488 (green), m α CD163+g α m polyclonal Alexa488 (green), and m α CD207+g α 
m IgG1 specific Alexa549 (orange).  Hoechst nuclear stain (blue). 
 
 
 
Figure 11: Cutaneous immune cell populations identified by in situ staining 
Mock inoculated skin sections (6µm) stained for: A) m α CD1c+g α m IgG1 specific Alexa549 (red) and m α 
CD1a+g α m IgG2a specific Alexa647 (yellow). Co-localization indicated by arrow heads. B) m α CD163+g α m 
IgG1 specific Alexa549 (red) and m α CD1a+g α m IgG2a specific Alexa647 (white). Circled is a dMØ.     C) m α 
CD206+g α m IgG1 specific Alexa549 (red) and m α CD1a+g α m IgG2a specific Alexa647 (yellow). Arrow head 
indicates co-localization. D) m α CD209+g α m IgG2b specific Alexa647 (red) and m α CD1c+g α m IgG1 specific 
Alexa549 (white). Hoechst nuclear stain (blue). Panels A and C depict representative staining from three 
independent replicates; panels B and D depict representative staining from two independent replicates. 
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Figure 11-A, shows co-localization of CD1a (yellow) and CD1c (red) in the dermis. This is 
the phenotype expected of dDCs (29). Bright staining for CD1a (yellow) is apparent in the 
epidermis; this indicates the presence of epidermal LCs (29). To confirm that CD1a expressing 
dermal cells are dDCs, it is necessary to establish that they do not express the scavenger receptor 
CD163 (27). Figure 11, panel B, image of reticular dermis cells, confirms that cells expressing 
CD1a (white) do not express the dMØ marker CD163 (red). It also highlights the fact that 
morphology cannot be used to differentiate dDCs from dMØs; the circled cell is a dMØ based on 
expression of CD163 but has an elongated, spindled, dendritic like appearance. 
The receptor profile of dDCs remains poorly defined, yet it is hypothesized that expression 
of DC-SIGN and MR makes dDCs targets of DENV infection (28). In order to clarify the issue, 
sections were stained with CD1a or CD1c and either CD206 (MR) or CD209 (DC-SIGN) (Figure 
11C and D). As expected, CD1a (white) is expressed in both the epidermis and the dermis. In the 
epidermis it does not co-localize with CD206/MR (red) which confirms that LCs do not express 
MR (Figure 11C). In the dermis some cells express both CD1a and CD206 while some have only 
CD206; these cells are likely dDCs and dMØs respectively. Unlike CD206/MR, CD209/DC-
SIGN is not co-expressed on cells with dDC markers. This is evident in Figure 11D, where CD1c 
(white) does not co-localize with CD209/DC-SIGN (red). Furthermore, since LCs do not express 
DC-SIGN (29), the CD209 positive cells in the dermis must be dMØ. 
These experiments clarified the phenotypes of immune cells in the skin. LCs can be 
identified in the epidermis based on expression of CD1a or CD207. The dermis contains dMØs 
defined by the expression of CD163. Additionally, dMØs can be identified by expression of DC-
SIGN since we have confirmed that this receptor is not expressed on DCs in the dermis. Dermal 
cells expressing CD1a, CD1c, and/or CD207 are dDCs or migratory LCs; additional staining 
would be necessary to differentiate these populations. 
3.3.3 DENV detection in skin 
Having validated the assay for phenotyping cutaneous immune cells, the subsequent studies were 
aimed at determining the degree of DENV infection in skin and specifying the cell types 
infected. The methods for DENV detection are detailed in section 3.2. Briefly, cryosections were 
stained with unconjugated or biotinylated primary antibodies (IgG, 2H2, or 15F3) overnight. 
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Polyclonal goat-anti-mouse antibodies used for virus detection were Alexa 488 or streptavidin 
Alexa-488 or -647. Staining in pre-fixed skin using unconjugated 2H2 is depicted in Figure 12A; 
background levels of fluorescence were established in mock infected skin. Staining above 
background is apparent in the cytoplasm of dermal resident cells (yellow). However, it is unclear 
whether these cells represent dMØs, dDCs, or migrating LCs. Additionally, the epidermis, 
particularly the stratum basale and stratum corneum, fluoresce uniformly in DENV+ skin to a 
greater degree than in mock infected skin. This is likely the detection of DENV infection in 
keratinocytes, however the use of a keratinocyte specific antibody would be required to confirm 
this hypothesis. Additionally, it is possible that prM protein in virus inoculum adheres to the 
dead keratinocytes of the stratum corneum and is detected in this most superficial layer of the 
epidermis. Similar results were seen staining with biotinylated 2H2 primary (on DENV+ and 
DENV- skin) followed by streptavidin Alexa488 (Figure 12B).   
 
 
 
Figure 12: DENV antigen is detectable in dermal and epidermal cells of inoculated skin 
A) PFA fixed skin sections (6µm) mock infected (left) or DENV infected (right) stained with unconjugated pan-DV 
antibody 2H2 + polyclonal g α m Alexa488 (yellow). B) PFA fixed skin sections (6µm) mock infected (left) or 
DENV infected (right) stained with biotinylated pan-DV antibody 2H2 + streptavidin g α m Alexa488 (green). 
Hoechst nuclear stain (blue). Images are representative of results from three independent replicates using skin 
explants from two individuals; skin inoculated via scarification. 
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These data suggest that DENV infection does occur in both dermal and epidermal 
populations of cutaneous cells; however it does not clarify the specific subpopulations of 
cutaneous immune cells that become infected with DENV. Multiple methods of dual staining, for 
DENV protein and cell-surface markers, failed to reveal appropriate staining patterns. 
Nonspecific binding of primary and secondary antibodies often resulted in apparent co-
localization of virus and cell marker in both DENV and mock infected skin sections. 
Additionally, the limited DENV antigen in the skin prohibited the additional blocking steps 
required to inhibit nonspecific co-localization. However, preliminary data suggest that these 
problems have been resolved with the following staining method: (1) blocking sections with goat 
serum (2) biotinylated mouse-anti-DENV-2H2 (3) streptavidin-goat-anti-mouse secondary (4) 
monoclonal mouse-anti-cell marker primary (5) goat-anti-mouse single Fab fragment secondary. 
This method has been used to assess the degree of infection in dDCs, dMØs, and LCs (Figure 
13). 
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Figure 13: Dermal resident MØs and DCs are targets of DENV infection 
A) PFA fixed skin sections (6µm) mock infected (left) or DENV infected (right) stained with biotinylated pan-
DENV antibody 2H2 + streptavidin g α m Alexa488 (green) and m α CD163 + single Fab fragment g α m Alexa 
546. Arrow head indicates co-localization, arrow indicates uninfected dMØ. B) PFA fixed skin sections (6µm) mock 
infected (left) or DENV infected (right) stained with biotinylated pan-DENV antibody 2H2 + streptavidin g α m 
Alexa488 (green) and m α CD1c + single Fab fragment g α m Alexa 546. C) Acetone fixed skin sections (6µm) 
mock infected (left) or DENV infected (right) stained with biotinylated pan-DV antibody 2H2 + streptavidin g α m 
Alexa488 (green) and m α CD207 + single Fab fragment g α m Alexa 546. Hoechst nuclear stain (blue). 
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DENV can be detected in CD163 expressing cells, suggesting that dMØs are targets of 
DENV infection (Figure 13A). In DENV inoculated skin explants, infected MØs reside in the 
lower papillary or upper reticular portion of the dermis, while uninfected dMØs are concentrated 
directly beneath the epidermis. This could indicate selective recruitment of uninfected MØs to 
the infected keratinocytes in the basal layer of the epidermis. It is likely that this reorganization 
of dMØs in DENV inoculated skin occurs to promote the clearance of virus and apoptotic 
keratinocytes. 
DCs located in the dermis are targets for DENV infection based on the co-localization of 
DENV antigen and CD1c in DENV inoculated skin (Figure 13B). It is unclear whether these 
cells represent dDCs or migratory LCs since CD1c is expressed on both of these cell types (32, 
33). DENV was not detected in epidermal LCs (Figure 13C); however, this does not indicate that 
LCs are unsusceptible to DENV infection. The frequency of cell specific DENV detection in the 
stratum spinosum and granulosum of the epidermis is consistently low relative to that in the 
dermis (see Figure 12), this could explain the failure to detect DENV in epidermal LCs. 
Alternatively, the overall lack of DENV detected in this staining could indicate that this section 
was far from the site of inoculation and is representative of bystander cutaneous cells. 
It is evident that DENV is capable of infecting both dMØs and some populations of dermal 
or epidermal DCs. Further studies will be required to confirm this finding and to clarify the 
effects of DENV infection. Upon pathogen recognition dMØs are capable of producing 
inflammatory cytokines that aid in the recruitment of additional immune cells from the blood 
(28). This could aid in the clearance of virus and the activation of adaptive immunity. However, 
it is unclear whether this occurs during DENV infection. In response to maturation stimuli, dDCs 
quickly mature up regulate expression of CCR7 and migrate to the cutaneous draining lymph 
node (31). However, in vitro studies suggest that DENV infection of dDCs does not stimulate 
maturation. This could render infected dDCs incapable of viral clearance and diminished in their 
capacity to activate adaptive immunity. It is difficult to speculate the effects that DENV infection 
would have on LCs, as the immunological role of LCs remains unclear (39-41).  
 37 
4.0  DISCUSSION 
Overall, the pathogenesis of DENV is poorly understood. It is suspected that cutaneous immune 
cells are primary targets of infection and that they contribute to viral dissemination and adaptive 
immune activation; however there is limited evidence to support this hypothesis (17). The lack of 
an appropriate animal model for DENV and the limited access to patient samples has made 
biologically relevant studies of DENV difficult to perform. Here, we used healthy human skin 
explants, in conjunction with human mdDCs, to study the degree of cutaneous infection and the 
potential role of cutaneous immune cells in DENV pathogenesis.     
It is currently hypothesized that initial DENV infection occurs in cutaneous immune cells 
and that subsequent migration of infected cells to the lymph node results in dissemination of 
virus (17). However, in vitro data presented here supports findings that viral infection does not 
stimulate the maturation of DCs (44). It is probable that insufficient maturation of DENV 
infected dDCs and LCs would render these immune sentinels incapable of migration out of the 
skin; this would limit the degree to which dDCs and LCs contribute to virus dissemination via 
the cutaneous draining lymph node. This is supported by the lack of DENV positive cells 
observed in emigrant skin cell populations. Additionally, our data confirm that dDCs do not 
express DC-SIGN (28) and that LCs lack defined DENV receptors (10, 11). It is possible that 
this indicates a reduced susceptibility of dDCs and LCs to DENV infection compared to dMØs. 
The expression of DC-SIGN and MR on dMØs suggests that they would be susceptible to 
DENV infection (10, 11, 29); a hypothesis confirmed here by immunolabeling of CD163 and 
DENV in ex vivo inoculated skin samples. In response to invading pathogen, the role of dMØs is 
primarily one of cytokine production and pathogen clearance; these cells have limited migratory 
and immunostimulatory capacities (27, 28). Also, infection of dMØs likely results in trafficking 
of DENV into poorly acidified phagosomes, thereby limiting viral replication (46). These facts 
indicate that dMØs do not contribute greatly to the amplification and dissemination of virus.  
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In addition to limiting the amount of viral replication and producing immune modulating 
cytokines, dMØs may contribute to DENV clearance. DENV inoculation of skin explants results 
in the infection of dMØs as well as an altered distribution of uninfected dMØs compared to 
mock infected skin. Dense populations of uninfected dMØs are evident in the papillary layer of 
the dermis, just deep to the epidermis. DENV infection of keratinocytes in the basal layer of the 
epidermis likely alters the immune environment such that these uninfected cells are recruited to 
this site. Here, dMØs may aid in the clearance of virus as well as apoptotic cell bodies. Further 
investigation of dMØs, as well as keratinocytes, is necessary to understand their dynamic roles in 
cutaneous DENV infection.    
The minimal detection of DENV infected cells in the dermis of skin sections suggests that 
the spread of virus within the skin is limited. Previous in vitro studies indicate that, while DENV 
infected DCs do not acquire a mature phenotype (44), they do produce TNF-α and IFN-α (49-51, 
54). IFN-α is likely produced following the recognition of dsRNA, the DENV replication 
intermediate (9), by TLR3. TLR3 is a potent inducer of type-I interferons (IFN-α and -β), which 
have antiviral and immunostimulatory effect on neighboring cells (58). Production of pro-
inflammatory and anti-viral cytokines by DENV infected cells may stimulate the maturation of 
bystander cells and the down-regulation of DC-SIGN (44). This would render bystander cells 
less susceptible to DENV infection. This supports the hypothesis that the spread of DENV within 
the skin is limited.  
Previous work has suggested that LCs are primary targets for DENV infection. Studies have 
identified DENV positive epidermal cells as LCs based solely on their epidermal location (43) or 
on their location and co-expression of CD1a (45). This work identified high levels of DENV prM 
protein in epidermal cells of inoculated human skin explants. However, this detection was 
primarily in the stratum basale and stratum corneum of the epidermis where LCs do not reside. 
Combined with the lack of detection in langerin+ cells of the dermis and epidermis, these data 
suggest that, while LCs may become infected, keratinocytes are the primary epidermal target of 
DENV. Additionally, it remains unclear how DENV infected LCs may contribute to DENV 
immunopathogenesis. Further, the immunological role of LCs is controversial. In vitro studies 
suggest that the primary function of LCs is the initiation of immune responses to epidermal 
threats (39). Contradictory in vivo data suggest that LCs are not necessary for the induction of 
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immune responses and may play an immunoregulatory role (39, 41). These inconsistencies 
further complicate our understanding of the role of LCs during DENV infection. 
The induction of adaptive immune responses is vital to the clearance of pathogens, 
especially intracellular pathogens such as DENV. DCs play a critical role here, in which they 
become active, mature, and migrate to the lymph node to activate T- and B-cell mediated 
responses. The results presented here indicate that DENV infected dDCs, and potentially LCs, 
may fail to contribute to the induction of adaptive immunity. Insufficient expression of the 
immune synapse molecules MHC-II, CD86 and CD83 on DENV infected mdDCs supports this 
hypothesis. While expression of MHC-II and CD86 are up-regulated on DENV infected DCs 
stimulated with soluble maturation stimuli, the expression of CD83 on these cells remains 
absent. It is likely that a yet unidentified viral factor is responsible for the specific down-
modulation of CD83 expression. This could represent an immune evasion technique of DENV. 
CD83 is known to reduce the threshold necessary for antigen specific B-cells activation (55), and 
it is probable that DENV down-modulates this molecule in an effort to inhibit the production of 
virus neutralizing antibodies. Additionally, a diminished capacity to migrate and present antigen 
to naïve T-cells allows DENV to avoid recognition and destruction by cell-mediated immunity. 
Further studies are needed to understand the mechanisms of how DENV causes these deleterious 
changes in DCs. 
In addition, we confirm that DCs become apoptotic upon DENV infection (44). This pro-
apoptotic effect of DENV was observed at MOIs as low as 1viral PFU/cell. We speculate that 
infected DCs that are incapable of maturation undergo programmed cell death. Further studies 
are needed to assess apoptotic effects of DENV infection in cutaneous immune cells.      
The work presented here has established an ex vivo model for further investigation of DENV 
infection in subsets of cutaneous immune cells, as well as to establish their consequent 
phenotype. Elaborating on these methods, cell-surface staining for maturation markers, including 
CD86, CD83 and CCR7, can be used to confirm whether DENV+ cutaneous immune cells 
acquire a mature phenotype. Additionally, this method can be used to confirm the pro-apoptotic 
effects of DENV infection that are observed in mdDCs. Furthermore, the use of this ex vivo skin 
model could be extended to studies of other arboviruses, such as West Nile virus (WNV). 
Similar to DENV, WNV is a reemerging infectious agent that causes life-threatening illness and 
is not preventable by vaccination (2). Elucidating the role of skin immune cells could aid in the 
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understanding of WNV pathogenesis and the development of a safe and effective vaccine. Also, 
this system could be used to study variability of virus infectivity in mosquito vs. vaccine 
infections. Limited studies suggest that the infectivity of DENV, and potentially other 
arboviruses, is affected by mosquito saliva (59). This warrants investigation as it could impact 
the efficacy of purified virus vaccines if cutaneous infection is a primary route of virus 
introduction. 
The incidence and severity of DENV cases have increased dramatically in recent years (4). 
Our current understanding of DENV pathogenesis is limited; this fact contributes to difficulties 
in developing effective vaccines and treatments. Due to the vector-borne nature of the virus, a 
primary target of infection is thought to be the skin immune system. Therefore, elucidating the 
effects of infection on cutaneous immune cells will be vital in our efforts to understand DENV 
pathogenesis and develop safe and effective therapeutic and preventative treatments.  
(60-67) 
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APPENDIX 
ANTIBODY INFORMATION 
Table 2: Maturation and apoptosis antibodies 
 
 
 
Table 3: Emigrant skin cell antibodies 
 
 
 42 
 
Table 4: In situ staining antibodies 
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